(R)-(+)-WARFARIN manufacturers
- (R)-(+)-WARFARIN
-
-
2026-06-30
- CAS:5543-58-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
|
| | (R)-(+)-WARFARIN Basic information |
| Product Name: | (R)-(+)-WARFARIN | | Synonyms: | 4-Hydroxy-3-[(1R)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-2-one;(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone;(S)-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin;r-(+)-3-acetonybenzyl)-4-hydroxycoumarin;2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (R)-;2H-1-Benzopyran-2-one, 4-hydroxy-3-[(1R)-3-oxo-1-phenylbutyl]- (9CI);Coumarin, 3-(a-acetonylbenzyl)-4-hydroxy-, R-(+)- (8CI);Dextrowarfarin | | CAS: | 5543-58-8 | | MF: | C19H16O4 | | MW: | 308.33 | | EINECS: | 226-908-9 | | Product Categories: | Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 5543-58-8.mol |  |
| | (R)-(+)-WARFARIN Chemical Properties |
| Melting point | ≥170 °C | | Boiling point | 515.2±50.0 °C(Predicted) | | density | 1.307±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMF: soluble | | pka | 4.50±1.00(Predicted) | | form | A crystalline solid | | color | white to pale yellow | | InChI | 1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3/t15-/m1/s1 | | InChIKey | PJVWKTKQMONHTI-OAHLLOKOSA-N | | SMILES | [H][C@@](CC(C)=O)(c1ccccc1)C2=C(O)c3ccccc3OC2=O |
| Hazard Codes | T | | Risk Statements | 61-48/25-52/53 | | Safety Statements | 53-45-61 | | RIDADR | UN 2811 6.1/PG 1 | | WGK Germany | 3 | | Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | | Hazard Classifications | Acute Tox. 1 Dermal
Acute Tox. 1 Inhalation
Acute Tox. 2 Oral
Aquatic Chronic 2
Repr. 1A
STOT RE 1 |
| | (R)-(+)-WARFARIN Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | (R)-(+)-warfarin has been used to investigate whether enantiomers of warfarin stereoselectively interact with pregnane X nuclear receptor (PXR) to upregulate main drug/xenobiotic-metabolizing enzymes cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2C9 (CYP2C9). It has also been used in HepG2 cells to study protein profiles | | Uses | The R-(+)-form of Warfarin (W498500). Coumarin anticoagulant. | | Definition | ChEBI: (R)-warfarin is a 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (R)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide). It is a conjugate acid of a (R)-warfarin(1-). It is an enantiomer of a (S)-warfarin. | | General Description | The chiral carbon at position 9 produces two enantiomers, R- and S-warfarin. Commercially available warfarin (Coumadin or Jantoven) is a racemic mixture of S- and R-enantiomers. | | Biochem/physiol Actions | Warfarin acts as a vitamin K antagonist. It is widely used to treat thromboembolic disorders. (R)-warfarin interacts with pregnane X receptor (PXR) and induces cytochrome P450 3A4 (CYP3A4) and CYP2C9 mRNAs expression in primary human hepatocyte cultures. |
| | (R)-(+)-WARFARIN Preparation Products And Raw materials |
|